Retatrutide is still under clinical investigation and is not a routinely prescribed medication
These side effects may recur when the person titrates the dose, Dawkins says
Anyone managing GLP-1 injection sites will find the administration technique identical, as the subcutaneous injection method is the same for both
The market is no longer defined only by weekly injections
The Trump administration has promoted Most-Favored Nation pricing initiatives aimed at preventing Americans from paying more than patients overseas, but the policies have faced legal challenges
The drug met the primary and key secondary endpoints, delivering superior A1C reduction and Lillys triple agonist achieves 16.8% weight loss in phase 3 trial Eli Lillys triple agonist, retatrutide, demonstrated an average weight loss of 16.8% in a Phase 3 trial for the treatment of type 2 diabetes, the company announced today